Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Miami, Florida

This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
12548
Shown on this page
12
Current sort
Recently updated
Location scope
Miami, FL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Miami, Florida. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 745–756 of 12,548 matching trials in Miami, FL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
No Longer Available No phase listed Expanded access

Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder

NCT07093541
View directory record Official record
Conditions
Tourettes Disorder, Tourette Disorder
Interventions
ecopipam HCl ~2mg/kg/day
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years to 50 Years
U.S. locations
26
States / cities
Glendale, California • San Rafael, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Recruiting Phase 2 Interventional

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

NCT07684820
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo
Drug
Lead sponsor
Expedition Therapeutics, Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
29
States / cities
Phoenix, Arizona • Encino, California • Northridge, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

NCT05595642
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Astegolimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
53
States / cities
Birmingham, Alabama • Dothan, Alabama • Glendale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Recruiting Phase 3 Interventional

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

NCT07602582
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Plaque, Amyloid
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
55
States / cities
Phoenix, Arizona • Huntington Beach, California • Irvine, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

NCT04770545
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
PEGCETACOPLAN (APL-2)
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
99
States / cities
Phoenix, Arizona • Bakersfield, California • Campbell, California + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Recruiting Phase 2 Interventional

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

NCT07226661
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
SPN-821 2400 mg, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Completed Phase 2 Interventional

A Study to Evaluate Solriktug in Adult Participants With Asthma

NCT06496607
View directory record Official record
Conditions
Asthma
Interventions
NSI-8226, Placebo
Biological
Lead sponsor
Uniquity One (UNI)
Industry
Eligibility
18 Years to 75 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
69
States / cities
Mobile, Alabama • Peoria, Arizona • Encinitas, California + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Recruiting Early Phase 1 Interventional

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

NCT04139304
View directory record Official record
Conditions
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Daratumumab, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Prednisone, Vincristine, Vincristine Sulfate
Drug · Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
9
States / cities
Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Completed Phase 3 Interventional

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

NCT06588738
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Envudeucitinib, Placebo, Apremilast
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Recruiting Phase 2 Interventional

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
176
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 143 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Recruiting Phase 3 Interventional

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Deucravacitinib, Ustekinumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
3,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
122
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST
Recruiting Phase 3 Interventional

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Trastuzumab Deruxtecan, Bevacizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
33
States / cities
Burbank, California • La Jolla, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 8:29 AM EST